Leading healthcare solutions company, with support from Novartis, aims to increase wide-scale population testing of Lipoprotein(a)

LetsGetChecked, a global healthcare solutions company, today announced its collaboration with Novartis to increase access to Lipoprotein(a)–Lp(a)–testing and programs. Now, Lp(a) will be measured in LetsGetChecked’s testing for Cholesterol and Diabetes & Heart, offering individuals an even more comprehensive assessment of key risk factors relating to cardiovascular health. Elevated Lp(a) affects an estimated 20% of the world population, but despite its prevalence is not typically included in routine lipid panels.¹ With the support of Novartis, LetsGetChecked is empowering individuals to take control of their health with convenience and efficiency, fostering a more equitable future of healthcare for all.

“We are thrilled to announce that we are working with Novartis to increase access to Lp(a) testing and help those who may be at risk better understand their cardiovascular health,” said Peter Foley, Founder and CEO of LetsGetChecked. “This unique collaboration demonstrates our commitment to innovation and precision-driven care, which propels us to continuously enhance our healthcare solutions, ensuring that individuals can make informed decisions and prioritize their well-being with ease and confidence.”

Lp(a) is a particle in the blood, made up of fats and protein. It can attach to the artery walls and cause harmful blockages. While it is normal for people to have some Lp(a) in their blood, the risk comes when the level is too high. In fact, elevated levels of Lp(a) may increase the chance of a heart attack or stroke by 2 to 4 times.¹ Unlike LDL-cholesterol that is often affected by both lifestyle and genetics, elevated Lp(a) is mainly inherited and is a highly prevalent genetic risk factor for heart disease.²

“Knowing your risk factors for heart disease are key to prevention,” said Dr. Robert Mordkin, Chief Medical Officer at LetsGetChecked. "By incorporating the Lp(a) biomarker into our heart health testing services and programs, we are empowering individuals to take control of their cardiovascular health through early insights and detection, ultimately producing better heart health outcomes,” he concluded.

Lp(a) is only measurable with a blood test. LetsGetChecked's heart health testing includes an at-home sample collection kit delivered directly to a patient's door and a prepaid shipping label to return the sample for testing. All samples are analyzed in LetsGetChecked’s laboratory, which is CLIA-certified and CAP-certified in the United States. Results are delivered online in 2-5 days with follow-up virtual consultations available if needed.

This announcement comes as LetsGetChecked continues to deliver on its mission to empower people to live longer, happier lives by providing the tools to manage health from home through health testing, genetic sequencing and insights, virtual care, and medication delivery for a wide range of health and wellness conditions. The company has served over ten million patients and more than 1,000 corporate customers with health testing and virtual care services since it was founded in 2015.

Patients can purchase testing for the Lp(a) biomarker directly from the LetsGetChecked website. Please visit www.letsgetchecked.com/lipoproteina-cholesterol-test/ to learn more.

About LetsGetChecked

LetsGetChecked is a global healthcare solutions company that provides the tools to manage health from home through health testing, genetic sequencing and insights, virtual care, and medication delivery for a wide range of health and wellness conditions. LetsGetChecked's end-to-end model includes manufacturing, logistics, lab analysis, physician support, and prescription fulfillment. Founded in 2015, the company empowers people with accessible health information and care to live longer, happier lives.

LetsGetChecked is available nationwide in the United States, the United Kingdom, and most EU countries. It is co-headquartered in Dublin and New York.

______________________________

¹ Wilson, Don P et al. “Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.” Journal of clinical lipidology vol. 13,3 (2019): 374-392. doi:10.1016/j.jacl.2019.04.010

² Tsimikas, Sotirios et al. “Unmet Needs in Understanding Lipoprotein(a) Pathophysiology: NHLBI Working Group Recommendations to Reduce Risk of Cardiovascular Disease and Aortic Stenosis.” J Am Coll Cardiol. 2018 January 16; 71(2): 177–192. doi:10.1016/j.jacc.2017.11.014

View source version on businesswire.com: https://www.businesswire.com/news/home/20230920241674/en/